BGOG-cx3

Prospective randomized Phase II trial comparing doxorubicin alone versus atezolizumab alone versus doxorubicin and atezolizumab in recurrent cervical cancer.

EUDRA-CT number: 2016-000547-14

 

Study sites:

  • UZ Leuven, Leuven
  • AZ Groeninge, Kortrijk
  • CHU de Liège Site Sart Tilman, Liège
  • CHU UCL Sainte-Elisabeth Namur, Namur
  • CHU Ambroise Paré, Mons
  • OLV Aalst, Aalst